Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Summary

A phase II randomized clinical trial was conducted to determine whether etoricoxib could prevent or ameliorate the incidence and/or severity of docetaxel-induced acute pain syndrome. We also aimed to determine if there are any improvement of the late-onset peripheral neuropathy as well as quality of life with prophylactic etoricoxib for breast cancer patients who receive docetaxel chemotherapy.

Timeline

Start

2020-03-01

Primary completion

2021-04-22

Completion

2021-06-28

Outcome

Met primary endpoint

paper etoricoxib group was 57.1%, while that in the control group was 91.5% (P < 0.001). PMID 35724467 ↗

Publications

• Zhang J, Gao HF, Yang C, Zhu T, Ji F, Yang M, Zhang L, Li J, Cheng M, Zhang T, Shen B, Chen Y, Wang K. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial. Eur J Cancer. 2022 Aug;171:150-160. doi: 10.1016/j.ejca.2022.05.019. Epub 2022 Jun 17.

Drugs

Indications